Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, for the Treatment of Ulcerative Colitis

Award Number: R43AI134205
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2017
PERIOD OF PERFORMANCE END DATE: 06/30/2018

Group Awards By:

View Award Description

Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, for the Treatment of Ulcerative Colitis - Vivreon Biosciences – NIAID SBIR # PA-16-302 Project Summary Vivreon Biosciences is pleased to apply for NIAID SBIR Solicitation #PA-16-302. Vivreon Biosciences is an innovative life sciences company that is developing a novel small molecule, Ca2+ channel inhibitor for the treatment of ulcerative colitis (UC). Our lead compound, VV2003, achieves immunosuppression by an entirely new mechanism – colon-restricted inhibition of Ca2+ release-activated Ca2+ (CRAC) channels to block colitis. Vivreon seeks NIAID funding to bridge the gap between discovery and development. We will perform formulation chemistry and in vivo colitis efficacy studies. Upon successful completion of the program, our preclinical candidate will be the first to specifically target the CRAC pathway for immunosuppression in UC, thus comprising an entirely new tool in the battle against inflammatory bowel diseases (IBD). Vivreon has discovered a lead compound VV2003, which inhibits inflammation by blocking CRAC channel activity with nM potency; suppressing M1-like NF-¿B activity, while preserving M2-like phagocytosis. Importantly, VV2003 has extremely low epithelial permeability, a key feature of many topical oral IBD therapeutics that remain in the gut lumen. This permits VV2003 to achieve colon-restricted immunosuppression, avoiding unwanted systemic side effects. We have developed several strategies for a novel oral colon-targeted delivery, and these routes will be pursued to identify a formulation suitable for future Investigational New Drug (IND)-enabling studies. The candidate will be confirmed using an animal model suitable for UC (adoptive transfer colitis, Dr. Cahalan, University of California, Irvine). The final aim for this proposal is characterization and testing of the first CRAC channel inhibitor for UC therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2017	VIVREON BIOSCIENCES, LLC	4940 CARROLL CANYON RD STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	1	1/8/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $219,975 )
2017	2017	VIVREON BIOSCIENCES, LLC	6990 CARROLL RD STE A	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	1	6/23/2017	NEW	$219,975
														Subtotal = $219,975

Grand Total All Awards = $219,975

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, for the Treatment of Ulcerative Colitis

Award Number: R43AI134205

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2017

PERIOD OF PERFORMANCE END DATE: 06/30/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer